Karyopharm Therapeutics
KPTI
75 hedge funds and large institutions have $135M invested in Karyopharm Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 13 closing their positions.
76% more call options, than puts
Call options by funds: $310K | Put options by funds: $176K
72% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 18
3% less funds holding
Funds holding: 77 → 75 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
28% less capital invested
Capital invested by funds: $187M → $135M (-$53M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.92M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$1.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.11M |
| 4 |
JP Morgan Chase
New York
|
+$708K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$432K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$8.71M |
| 2 |
Millennium Management
New York
|
-$5.13M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$765K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$599K |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$534K |
KPTI Hedge Fund Activity: Q2 2016 in Review
75 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2016, worth a combined $135M — down 28% from $187M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KPTI and 11 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 31 added.
The largest buyer was Wellington Management Group, adding an estimated $1.92M. The largest seller was Franklin Resources, cutting an estimated $8.71M.
- 75 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2016, down from 77 in Q1 2016.
- Funds reported $135M of Karyopharm Therapeutics stock for Q2 2016, down 28% quarter-over-quarter.
- 11 funds opened new Karyopharm Therapeutics positions in Q2 2016 and 13 closed out, a net change of -2 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2016 was Wellington Management Group, an estimated $1.92M added.
- The largest Karyopharm Therapeutics seller in Q2 2016 was Franklin Resources, an estimated $8.71M sold.
Based on aggregated 13F filings for Q2 2016.